Predicting patient response to gleevec in gastrointestinal stromal tumours

Researchers at Fox Chase Cancer Centre uncovered a genetic pattern that may help predict how gastrointestinal stromal tumour (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumours respond more readily to imatinib...

Read the whole article on

More from